Although PLX3397 monotherapy did not significantly reduce tumor size in this study, it induced changes in immune composition, including a reduction in M2 macrophage abundance and infiltration of CD8-positive T cells into the tumor. The gene discussed is CD8A; the disease is neoplasm.